US FDA extends review of Humacyte's blood vessel implant
Updates share movement in paragraph 1, adds background in paragraphs 5-6
Aug 9 (Reuters) -Humacyte HUMA.O said on Friday the U.S. health regulator has extended review of the company's implant that can act as a replacement for an injured or damaged blood vessel, sending its shares down more than 15% after the bell.
The Food and Drug Administration needed additional time to complete its review and did not disclose a new decision date, the company said. The agency was set to announce its decision on Aug. 10.
The implant, known as Human Acellular Vessel (HAV), is made of biologically engineered human tissue that is universally implantable and resists the possibility of infection.
HAV can be used to treat patients with injured blood vessels who do not have a synthetic blood vessel prescribed to them or cannot use a healthy vein from the body as replacement.
The company estimates that 10,000 to 30,000 patients get affected with blood vessel injuries annually in the United States.
Its application to the FDA was based on a mid- to late-stage study, where HAV showed higher rates of blood flow and lower rates of infection compared to synthetic implants.
Reporting by Christy Santhosh; Editing by Shilpi Majumdar
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
